Denosumab launched in first indications in Japan through Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Local licensee Daiichi Sankyo has launched Amgen's antibody denosumab for its first indications in Japan, as Ranmark for bone disorders stemming from bone metastases of solid tumours and bone complications of multiple myeloma.